Enzyme News and Research

RSS

Platelets may be contributing to COVID-19

The current pandemic of COVID-19 is characterized mainly by severe acute respiratory distress of the lungs, but other organ dysfunctions are also being observed, including the heart and blood vessels. Now, a new paper published on the preprint server medRxiv* in June 2020 describes the abnormal activation of platelets in this disease and the link between this phenomenon and poor outcomes for COVID-19 patients.

24 Jun 2020

A metabolic enzyme drives B cell lymphomas and could be a potential drug target

Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target.

24 Jun 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

ACE inhibition in kidney could influence pathogenesis of SARS-CoV-2

The dynamics of angiotensin-converting enzyme 2 (ACE2) expression in the kidney could have implications for the infectivity and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), say researchers.

24 Jun 2020

Structured 'cut-and-paste' design enables streamlined development of SARS-CoV-2 molecular probes

A seminal study by US researchers, currently available on the bioRxiv* preprint server, demonstrates how structure-based design can be efficiently employed to develop molecular probes targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and its domains, with possible future use in diagnostics, treatment and vaccine development.

24 Jun 2020

Statin therapy linked to lower death rate in hospitalized patients with COVID-19

The use of cholesterol-lowering drugs called statins is associated with a lower death rate and a lower incidence of mechanical ventilation in patients hospitalized with Coronavirus disease 2019 (COVID-19), researchers report June 24 in Cell Metabolism.

24 Jun 2020

Transgenic rice containing anti-hypertensive peptides lowers blood pressure in hypertensive rats

In the future, taking your blood pressure medication could be as simple as eating a spoonful of rice.

24 Jun 2020

Researchers investigate nelarabine drug for treating leukemia

Acute lymphoblastic leukemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine.

24 Jun 2020

New technique helps measure dNTP concentrations with greater sensitivity

A highly sensitive and easy-to-use technique applicable for tissue samples can be useful, for example, to researchers specialised in mitochondrial diseases and cancer.

24 Jun 2020

Abnormal findings in testicular tissue of COVID-19 patients, SARS-CoV-2 mostly undetected

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 9.263 million cases and taken more than 477,000 lives as of June 24, 2020 – just six months after the initial outbreak in Wuhan, China, was reported. The illness, called COVID-19 disease, caused by SARS-CoV-2 is a severe pneumonic illness, caused by the entry of the virus into the type II alveolar cells.

24 Jun 2020

Evidence of link between ACE2 genotype and COVID-19 disease severity

A new study published on the preprint server medRxiv in June 2020 shows that variants in the ACE2 gene which encodes the enzyme receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease, are linked to the risk of severe disease.

24 Jun 2020

Researchers report a key breakthrough to help protect newborns from brain damage

Oxygen deprivation can be the worst start to a newborn's life, resulting in brain damage, epilepsy, developmental delays and death.

23 Jun 2020

Bioactive factors-imprinted scaffold vehicles for boosting bone repair

Announcing a new article publication for BIO Integration journal. In this review article the authors Peng-Peng Xue, Jian-dong Yuan, Qing Yao, Ying-Zheng Zhao and He-Lin Xu, from Wenzhou Medical University, Wenzhou City, China consider bioactive factors-imprinted scaffold vehicles for promoting bone healing.

23 Jun 2020

Smoking increases risk of COVID-19 for men but not women

Even as the COVID-19 pandemic continues to spread over the world, scientists have had to come to terms with the fact that they don’t know much about the SARS-CoV-2 or the disease it causes. Now, a new study by researchers at the University College Cork, Ireland, and published on the preprint server medRxiv in June 2020 discusses the differences in COVID-19 risk between men and women who smoke.

23 Jun 2020

Pangolin version of SARS-CoV-2 can cause COVID-19-like illness

The results of a recent multinational research endeavor, currently available on the bioRxiv preprint server, display the biological framework of SARS-CoV-2-related coronavirus in pangolins and reveal striking similarities to coronavirus disease (COVID-19) in humans, but also show that it can be transmitted vertically to the fetus.

23 Jun 2020

FDA approved drugs active against COVID-19

With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.

23 Jun 2020